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(57) 	 ABSTRACT 
A universal detection system based on allosteric aptamers, 
signal amplification cascade, and eye-detectable phrase tran-
sition. A broadly applicable homogeneous detection system 
is provided. It utilizes components of the blood coagulation 
cascade in the presence of polystyrene microspheres (MS) as 
a signal amplifier. Russell's viper venom factor X activator 
(RVV-X) triggers the cascade, which results in an eye-visible 
phase transition precipitation of MS bound to clotted fibrin. 
An allosteric RNA aptamer, RNA132, with affinity for 
RVV-X and human vascular endothelial growth factor 
(VEGF 165) was created. RNA132 inhibits enzymatic activity 
of RVV-X. The effector molecule, VEGF 165, reverses the 
inhibitory activity of RNA132 on RVV-X and restores its 
enzymatic activity, thus triggering the cascade and enabling 
the phase transition. Similar results were obtained for another 
allosteric aptamer modulated by a protein tyrosine phos-
phatase. The assay is instrumentation-free for both process-
ing and readout. 
16 Claims, 11 Drawing Sheets 
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Schematic Representation of the Detection System based on 
Blood Coagulation Cascade with Microspheres (BCC-MS) 
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Inhibitory effect of RNA37s on the RW X-induced phase 
transition in the BCC-MS detection system 
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The effect of VEGF 165  on the inhibitory action of RNA132 on 
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Visual presentation of the kinetics of phase transition in the RNA 132-controlled 
BCC-MS detection system in the presence of different proteins 
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UNIVERSAL FIELDABLE ASSAY WITH 
UNASSISTED VISUAL DETECTION 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
The present application claims priority to U.S. Provisional 
Patent Application Ser. No. 60/779,994, filed on Mar. 6, 2006. 
FUNDING 
This invention was made with support in part by grants 
from the National Science Foundation (CCF-0323749), the 
Defense Advanced Research Projects Agency Office of 
Naval Research (DARPA-ONR; N00014-98-1-0664), and 
the United States National Aeronautics and Space Adminis-
tration (NASA; NCC2-1224). Therefore, the U.S. govern-
ment has certain rights. 
FIELD OF THE INVENTION 
The present invention relates in general to aptamers. More 
specifically, the invention provides a universal detection sys-
tem based on allosteric aptamers, signal amplification cas-
cade, and eye-detectable phrase transition. 
BACKGROUND OF THE INVENTION 
Detecting specific molecules is a crucial task for medicine, 
biotechnology, chemical and biodefense, and environmental 
protection. Many new detection systems are developed every 
year with increasing specificity and sensitivity. These sys-
tems include the latest developments in biotechnology and 
nanotechnology. All of them have one common feature: they 
employ sophisticated and expensive equipment for the pro-
cessing and/or the readout of the results. 
SUMMARY OF THE INVENTION 
A broadly applicable homogeneous detection system has 
been developed. It utilizes components of the blood coagula-
tion cascade in the presence of polystyrene microspheres 
(MS) as a signal amplifier. Russell's viper venom factor X 
activator (RVV-X) triggers the cascade, which results in an 
eye-visible phase transition precipitation of MS bound to 
clotted fibrin. An allosteric RNA aptamer, RNA132, with 
affinity for RVV-X and human vascular endothelial growth 
factor (VEGF 165) was created. RNA132 inhibits enzymatic 
activity of RV V-X. The effector molecule, VEGF 165 , reverses 
the inhibitory activity of RNA132 on RVV-X andrestores its 
enzymatic activity, thus triggering the cascade and enabling 
the phase transition. As few as five femtomoles of VEGF115 
could be detected by the naked eye within an hour. Similar 
results were obtained for another allosteric aptamer modu-
lated by a protein tyrosine phosphatase. The assay is instru-
mentation-free for both processing and readout and can be 
modified to detect molecules to which aptamers can be 
obtained. 
The above-mentioned and other features of this invention 
and the manner of obtaining and using them will become 
more apparent, and will be best understood, by reference to 
the following description, taken in conjunction with the 
accompanying drawings. The drawings depict only typical 
embodiments of the invention and do not therefore limit its 
scope. 
BRIEF DESCRIPTION OF THE FIGURES 
2 
cascade triggered by the different concentrations of RVV-X. 
(A) Visual presentation of the 96-well plate obtained on a 
flatbed scanner at the time of 50% reduction in absorbance 
4112) for a given concentration of RV V-X. (B) Optical density 
5 at 405 nm measured on a microplate reader in the same wells 
at 5-minute intervals. 
FIG. 2. Schematic representation of the secondary struc-
ture folding for the RNA aptamers. (A) RNA37s (SEQ ID 
NO: 1). (B) VTt44(-2) (SEQ ID NO:2). (C) RNAI32 without 
10 pseudoknots (SEQ ID NO:3). (D) RNA132 with pseudoknots 
(SEQ ID NO:4). 
FIG. 3. Kinetics of the phase transition in the BCC-MS 
detection system. (A) In the presence of different concentra-
tions of RNA37s. (B) The reversal of the inhibitory effect of 
15 RNA132 on the phase transition by different concentrations 
of Human VEGF 165 and PTPase. The relative effect was cal-
culated according to the formula in the Experimental Proce-
dures section. 
FIG. 4. Gel-shift analysis of RVV-X and Human VEGF115 
20 binding to RNA37s and RNA132. 
FIG. 5. Visual presentation of the kinetics of clot formation 
in the RNA132-controled BCC-MS detection system in the 
presence of 10 fmole of different proteins, except for 100 
amole of RNase. Proteins were incubated with a mix of 
25 RVV-X and RNA132 for 15 minutes at room temperature in 
5-10 µL of IC buffer, followed by the addition of the compo-
nents of the BCC-MS detection system. At the indicated time 
points, wells of the 96-well plate were scanned on a flatbed 
scanner. The results are presented in duplicates. 
30 	 FIG. 6. Phase transition (precipitate formation) caused by 
RVV-X in BCC-MS detection system. 
FIG. 7. Kinetics of phase transition (precipitate formation) 
caused by RVV-X in BCC-MS detection system. 
FIG. 8. Schematic representation of the detection system 
35 based on blood coagulation cascade with microspheres 
(BCC-MS). 
FIG. 9. Inhibitory effect of RNA37s on the RW-X-induced 
phase transition in the BCC-MS detection system. RNA37s 
was incubated with RVV-X for 15 minutes at room tempera- 
40 ture. One hundred microliters of the BCC-MS reaction mix 
were dispensed into wells of a 96-well plate to which 5-10 mL 
of a test solution were added. After that the plate was imme-
diately placed into a microplate reader (Genios, Tecan) and 
shaken for 10-30 seconds prior to OD 405 measurements at 
45 5-10 minute intervals. 
T(50) is the time for a 50% decrease in OD4o5- 
 
FIG. 10. The effect of VEGF 165 on the inhibitory action of 
RNA132 on RVV-X in RNA132-controlled BCC-MS detec-
tion system. In the RNA132-controled BCC-MS experiment, 
50 VEGF 165 reversed inhibitory action of RNA132 on the RVV-
X-triggered phase transition in a concentration-dependent 
mode. This effect implies competition between VEGF 165 and 
RV V-X for binding to RNA132. Dynamic range of the detec-
tion system appeared to be narrow, i.e. about I0-fold range of 
55 VEGF 165 concentrations (6-60 fmol/reaction mix), which is 
typical for BCC-based assays. The above sensitivity of the 
assay is within the lower half of the linear range of the 
VEGF 165 concentrations detected by ELI SA assays commer-
cially available from, e.g., R&D Systems or Cell Sciences. 
60 But components of the BCC-MS detection system presented 
here allow adjusting their relative concentrations to detect the 
molecule of interest within a wider range of concentrations. 
The formula to calculate relative effect of different concen-
trations of VEGF165 is as follows: 
65 
	
FIG. 1. Kinetics of the phase transition (precipitation of 	 (T (50) +RNA1321- VEGF165_T (50) +RNA1321 +VEGF165)/ 
	
MS bound to the clotted fibrin) in the BCC-MS amplification 	 (T (5 0)+RNA 1321 -VEGF 165- T(5  0) _RNA 132/ +VEGF 165) 
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FIG. 11. Visual presentation of the kinetics of phase tran- 	 Advantages of the above detection system include: only two 
sition in the RNA132-controlled BCC-MS detection system 	 pipetting cycles (compared with approximately 10 in 
in the presence of different proteins. Five femtomoles of 
	
ELISA), no washes, no reagents immobilized on solid sup- 
different proteins (except for 100 fmole of RNase) were incu- 	 port, and visual readout without any instrumentation. 
bated with a mix of RV V-X and RNA132 for 15 minutes at RT 5 SELEX 
in 5-10 uL of IC buffer, followed by the addition of the 	 An RNA aptamer binding to RVV-X was obtained via 
components of the BCC-MS detection system. At the indi- 	 standard SELEX protocol. The progress of the selection was 
cated time points, wells of the 96-well plate were scanned on 	 monitored by determining the dissociation constant of the 
a flatbed scanner. The results are presented in duplicates. 	 RNA-protein complex (Kd) and by determining how much 
Human VEGF 1651 Murine VEGF 165 and Zebrafish 10 RNA binds to a single "high" concentration (50 nM) of the 
VEGF 165 have both the same biological function and contain 	 protein target in a single point binding assay. Initial pool of 
165 of amino acids. Murine VEGF 165 has an 89% homology 	 unselected RNA (RNAO) had a Kd value of 550±30 nM with 
with Human VEGF 165 where 147 of 165 amino acids are 	 the binding of 6.3% in a single point binding assay when the 
identical. Zebrafish VEGF 165 has about a 62% amino acid 
	
IC binding buffer was used for washing and 2.2% when IC 
sequence identity with HumanVEGF 165 . HumanVEGF 121  is 15 binding buffer+300 mM NaCl (high salt) was used for wash- 
a truncated version of Human VEGF 165 , with 44 amino acids 	 ing, with 1.2% background noise. After five rounds of selec- 
truncated downstream from position 110 of the polypeptide 	 tion, Kd for RNA5 dropped to 22±3.0 nM; binding in a single 
chain. Thus cysteine 137 of VEGF 165 that forms a photo- 	 point binding assay increased to 23% and 7% respectively. An 
inducible cross-link to a uridine at position 14 of RNA VTt44 	 attempt to clone and sequence at this point failed to produce 
(which corresponds to position 13 of RNA VTt44(-2) and 20 a consensual sequence of reasonable length. After the ninth 
position 18 of RNA132) is missing in VEGF121• Human 	 round of selection, K d for RNA9 went down to 2.2±0.9 nM, 
VEGF/P/GF heterodimer is a protein artificially dimerized in 	 and the results for the single point binding assay were 55% 
vitro. It consists of Human VEGF 165 and Placental growth 	 and 43% respectively, with 2% background noise. A consen- 
factor. Endocrine gland VEGF is a protein of irrelevant amino 	 sual sequence for RNA9c was derived from the analysis of 45 
acid sequence consisting of 86 amino acids. 	 25 clones. 
The full length RNA9c (87 bases) containing a consensual 
DETAILED DESCRIPTION OF THE INVENTION 	 40-mer sequence flanked by the primers showed inhibitory 
activity of 43% in the RV V-X-SPZXa test. A systematic dele- 
Aptamers play an increasingly important role in biotech- 	 tion mutagenesis applied to RNA9c allowed to isolate 43-mer 
nology and nanotechnology. They can acquire allosteric 30 RNA37s. RNA37s showed 84% inhibitory activity in the 
properties similar to enzymes. There is no established termi- 	 RVV-XSPZXa test. It also showed concentration-dependent 
nology in the field, and these aptamers are variously called 	 inhibitory effect on the RV V-X-induced clot formation in the 
allosteric, ligandregulated, ligand-dependent, structure- 	 BCC-MS detection system. 
switching signaling, or modular. Armed with fluorophores, 	 An aptamer binding to VEGF165,  RNA VTt44, with one 
these aptamers can be used for detecting `effector' molecules, 35 base snipped from both 5'- and Y-ends (VTt44(-2), was 
where the readout is performed using the spectrofluorometer. 	 inserted into RNA37s five bases downstream from its 5'-end 
In order to free the readout procedure from any kind of instru- 	 to create an allosteric aptamer RNA132. This structure 
mentation, an approach utilizing biochemical amplification is 	 appeared to be more stable with AG-24.0 kcal/mol, com- 
explored. 	 pared with the "head to tail" version, when RNA37s was 
The biochemical amplification, resulting in an eye-detect-  40 directly linked with the Y-end of RNA VTt44(-2), AG-18.0 
able phase transition, is accomplished using the components 	 kcal/mol (28-30). It is important to note that theputative RNA 
(Factors X, Va, Prothrombin, and Fibrinogen) of the blood 	 binding domains for both proteins stayed unhampered in the 
coagulation cascade (BCC). When a specific metalloprotein- 	 chimeric RNA132. A possible conformation including 
ase, the Russell's viper venom factor X activator (RVV-X), is 	 pseudoknots was also predicted with AG-27.0 kcal/mol. 
added to the components of BCC, the cascade is triggered. 45 	 The following examples are intended to illustrate, but not 
Triggering of BCC in the context of polystyrene micro- 	 to limit, the scope of the invention. While such examples are 
spheres (MS) results in the eye-detectable clot formation 	 typical of those that might be used, other procedures known to 
(precipitate of MS bound to fibrin). An RNA aptamer 	 those skilled in the art may alternatively be utilized. Indeed, 
(RNA37s) was SELEXed to RVV-X. When RVV-X is mixed 	 those of ordinary skill in the art can readily envision and 
with RNA37s, and the resulting product is added to the com-  50 produce further embodiments, based on the teachings herein, 
ponents of BCC, clot formation is delayed. 	 without undue experimentation. 
The fusing of RNA37s to another aptamer (RNAVTt44), 
which binds to human Vascular Endothelial Growth Factor 	 EXAMPLES 
(VEGF165), produced a fusion-aptamer RNA132. When 
RVV-X is mixed with RNA132 and the resulting product is 55 	 This invention presents an approach for a broadly appli- 
added to the components of BCC, clot formation is also 	 cable detection system without using any instrumentation for 
delayed. However, when RVV-X is mixed with RNA132 and 
	
both processing and readout. 
then VEGF 165 is added, the resulting product does not delay 	 In the last several years aptamers have become widely used 
clot formation when added to the components of BCC. Hence 	 as sensors and diagnostic agents with a high level of speci- 
RNA132 is an allosteric aptamer. The sensitivity of the above 60 ficity and sensitivity (1-10). Among other advantages, aptam- 
assay for VEGF 165 is essentially the same as the sensitivity of 	 ers can be used in homogeneous assays, thus eliminating 
commercially available ELISA. Similar results were obtained 	 reagent immobilization and reducing processing time and 
for another allosteric aptamer (RNA37sN71 (SEQ ID NO: 5)) 	 manipulation steps (4, 10). Aptamers can acquire allosteric 
that was created by fusion of RNA37s with an aptamer for a 	 properties similar to enzymes (8, 11-16), and therefore they 
protein tyrosine phosphatase from Yersinia enterocolitica. 65 can be used for detecting `effector' molecules (8, 15). To 
Presumably this method can be used to create detection sys- 	 achieve the level of sensitivity that rivals more conventional 
tems for other molecules to which aptamers can be selected. 	 immunoassays (1, 2, 15), aptamer-based detection systems 
US 8,324,357 B2 
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also have to use sensitive and sophisticated instrumentation 
for processing and readout. In order to free the readout and the 
processing procedure from any kind of instrumentation, an 
approach is explored based on allosteric aptamers controlling 
the biochemical amplification cascade. The biochemical 
amplification cascade is based on the components of the 
blood coagulation cascade (BCCJ in the presence of poly-
styrene microspheres (MS). BCC-MS amplification cascade, 
results in an eye-visible phase transition, i.e. the precipitation 
of MS bound to the clotted fibrin. Controlled by an allosteric 
aptamer, BCC-MS amplification cascade becomes BCC-MS 
detection system. 
Experimental Procedures 
Materials. All plasticware including 96-well plates (flat 
bottom) used in this study were non-stick or low binding from 
Ambion and Corning. RNase-free water was from Ambion. 
Reagents for the human blood coagulation cascade: Fibrino-
gen, Prothrombin, Factor Va, Factor X and also snake venom 
protease RV V-X and pho spholipid vesicles (PCPS) were pur-
chased from Haematologic Technologies. 
SPECTROZYME®fXa (SPZXa) was from American Diag-
nostica. PCR and RT-PCR reagents and T7 RNA Polymerase 
kits were from Promega and Epicentre. Human VEGF,151 
human VEGF1211  murine VEGF 1651 zebrafish VEGF,151 
endocrine gland VEGF, and human VEGF/P1GF heterodimer 
were from R&D Systems and USB. Polystyrene micro-
spheres were from Bangs Laboratories. Ready-made poly-
acrylamide gels were from Invitrogen. Oligonucleotides were 
synthesized and purified by IDT or Qiagen. 
All reactions took place in 50 mM imidazole-HCl, 3 mM 
CaC12 buffer, pH 7.8, (IC buffer). Snapshots of the 96-well 
plates were taken by a Memorex flatbed scanner, model 
6142u. BCC-MS Amplification Cascade. A typical reaction 
mix contained 600 nM PCPS, 230 nM Fibrinogen, 170 nM 
Prothrombin, 870 IM Factor Va, 580 pM Factor X and 1/450-
1/350 dilution of polystyrene microspheres (10% solids) 
0.77-1.0 µm in diameter in IC buffer. One hundred microliters 
of the reaction mix were dispensed into wells of a 96-well 
plate to which 5-10 µL of a test solution, e.g. RVV-X, were 
added. After that the plate was immediately placed into a 
microplate reader (Genios, Tecan) and shaken for 10-30 sec-
onds prior to OD405 measurements at 5-10 minute intervals. 
The relative effect (zero meaning no effect, and one meaning 
maximal effect) of VEGF 165 on the inhibition of the phase 
transition by RNA132 was calculated according to the for-
mula, which allowed graphic presentation for the dynamic 
range of the reaction: 
(t12 +RN-1 132/-VEGF165 -t1, ,RNA 1321+VEGF165) 
(t12 	 -t12 +RNA 132/-VEGF165 	 -RNA1321+VEGF165\ 
where t112  is the time for a 50% reduction in absorbance. The 
same formula was applied for the calculation of the relative 
effect for PTPase. 
The BCC-MS reaction can be "frozen" at any stage by 
adding EDTA to 10 mM final concentration. 
SELEX Protocol and the Creation ofAllosteric Aptamers. 
Sequences for the initial DNA template library (40N) and 
primers for the SELEX for aptamer to RVV-X were taken 
from (17). Large-scale PCR amplification and all other sub-
sequent synthetic and selection steps were performed as 
described in (17-19) without modification. The initial selec-
tion involved 500 picomoles of random RNA library (3x 10 14 
molecules). After each round of selection RNA was tested in 
a nitrocellulose filter binding assay to determine the dissocia-
tion constant of aptamer-protein complexes (K,) (19) and in a 
single point binding assay with equimolar concentrations of 
protein and RNA (50 nM) (20). In the latter experiments one 
6 
set of filters was washed with IC buffer. Another set of filters 
was washed with IC buffer+300 mM NaCl (high salt buffer) 
to remove more of non-specifically bound RNA. After the 
fifth and ninth round of selection, RNA was reverse tran- 
s scribed, DNA was amplified by PCR and cloned. Each time 
45 clones were sequenced to determine the presence of con-
sensus sequences. Cloning and sequencing were performed 
by Laragen. 
Three VEGF 165 -binding RNA aptamers, 12t, 84t and 100t 
l0 described in (21), and three other VEGF 165 -binding RNA 
aptamers, VPt2, VPt22 and VTt44 described in (22), were 
synthesized using unmodified NTPs and tested in a gel-shift 
assay with VEGF 165 . Aptamer VTt44 showed the highest 
15 affinity for VEGF 165 in the IC buffer, since it was initially 
selected in the presence of calcium, which was absolutely 
required for high affinity binding of this aptamer to VEGF165 
(22). Please note that Ca ions are essential for BCC-MS 
amplification cascade. 
20 	 Allosteric aptamers were created either by directly fusing 
of the 5'-end of RNA37s with the 3'-end of an effector aptamer 
or by inserting an effector aptamer RNA a number of bases 
downstream into the RNA37s. 
RVV-X 	 Activity 	 Determination 	 with 
25 SPECTROZYME®fXa (RVV-X-SPZXa Assay). 
SPECTROZYME®fXa is a chromogenic substrate for the 
activated Factor X. RVV-X by itself (10 µL, 1.7 nM) or 
pretreated with aptamers (17 nM) was incubated with Factor 
X (170 nM) and mixed with 140 µL of 
30 SPECTROZYME®fXa (5 mM, IC buffer). Appearance of the 
chromophore, p-nitroanilide acetate, was monitored over 
time at 405 mu in a microplate reader. The final measurement 
was taken 10 minutes after the onset of the reaction. The 
35 inhibitory effect of an aptamer on the RVV-X activity was 
calculated according to the formula: 
[1- (ARw-X RIVA_ Anry )I(Vw-x_Anry )].100%. 
RNA Folding and Minimum Free Energy Calculations. 
40 Predictions of the RNA folding patterns with or without 
pseudoknots and calculations of minimum free energy (AG) 
were done according to algorithms and software presented in 
(23, 24). Visual representation of the RNA secondary struc-
ture based on the above predictions was done using Pseudo- 
45 Viewer2 software (25). 
DNA CompetitionAssay for Mapping of RNA132 Binding 
Sites for RVV-X and VEGF 165 . DNA molecules complemen-
tary to various segments of RNA132 were synthesized (see 
the list in Table 1) and used as competitors to RVV-X and 
50 VEGF165 in binding to 32P-labeled RNA132. The complexes 
were analyzed in a gel-shift assay utilizing 6% PAGE (0.5x 
TBE). RNA132 (100 fmol) was annealed with DNA (200 
fmol) by incubating the mix at 70° for 1 minute with slow 
cooling to room temperature. Proteins were added to the 
55 complex at room temperature and after 15 minutes of incu-
bation the samples were subjected to PAGE. Volumes for 
bands, determined by Phosphorimager "Storm" (Molecular 
Dynamics), corresponding to RNA132 complexes with 
RVV-X or VEGF165,  with no competing DNA added, were 
60 taken as 100% binding. When a full-length DNA complement 
(DNA I) was competing with the proteins for binding to 
RNA132, no bands corresponding to the RNA-protein com-
plexes were detected for either of the proteins, thus binding 
for them was 0%. In a control experiment proteins were 
65 annealed with the DNA used at tenfold higher concentrations. 
No binding was detected between competing DNA and the 
proteins. 
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TABLE 1 
Mapping of RNA132 binding sites for RVV-X 
and VEGF165 in a DNA competition assay. 
Base position 	 Percent binding 
DNA 	 number 	 RVV-X 	 VEGF165 
None added N/A 100 100 
I 1-68 0 0 
II 31-68 10 48 
III 36-68 17 64 
IV 1-30 19 14 
V 6-30 28 36 
VI 8-28 51 42 
Results 
Homogeneous BCC-MS Amplification Cascade. A bio-
chemical signal amplification cascade, utilizing components 
of the BCC cascade in the presence of MS was described as a 
part of a heterogeneous ELISA assay (26). The BCC portion 
of the amplification cascade consisted of Factors X, Va, II 
(Prothrombin), and I (Fibrinogen). BCC was triggered by a 
specific metalloproteinase, the Russell's viper venom factor 
X activator (RVV-X) (27). RVV-X-initiated BCC resulted in 
an eye-visible phase transition, i.e. precipitation of MS bound 
to the clotted fibrin. The assay showed sensitivity of 10-100 
fg/ml for RVV-X, which corresponds to 10-100 zeptomoles 
of the protein detected in 100 ltL of a test solution in 60 
minutes. The disadvantages of the above assay include its 
basis on a standard solid support ELISA format that requires 
multiple washes and reagent transfers. Furthermore, the 
above assay relies on several specific, not readily available 
reagents, one of which is a monoclonal antibody conjugated 
to RVV-X (26). 
This invention provides an effective approach overcoming 
these issues. An allosteric aptamer would substitute for anti-
bodies and conjugates, and would render the assay homoge-
neous, eliminating washing and minimizing reagent transfer 
steps. An allosteric aptamer will bind to RV V-X and inhibit its 
enzymatic activity, while subsequent binding of an effector 
molecule to the aptamer will modulate the inhibitory effect by 
reversing it. Thus, an on/off switch for the RVV-X activity 
will be created depending on the presence of an effector 
molecule. The allosteric aptamer-controlled detection system 
based on BCC in the presence of MS (BCC-MS) will require 
only one variable component apartoftheallostericaptamer 
specific to the effector molecule. 
Components for the homogeneous BCC-MS amplification 
cascade were derived from (26, 28). Modifications included 
substitution of the Factor V with the Factor Va, and substitu-
tion of the rabbit brain cephalin with the commercially avail-
able phospholipid vesicles. FIG. 1 shows the kinetics of the 
phase transition (clot formation) caused by the RVV-X activ-
ity in the BCC-MS amplification cascade monitored both 
visually and spectrophotometrically at 405 mu. Snapshots of 
the wells taken at the time of 50% reduction in absorbance 
(t112) for different RVV-X concentrations show distinct dif-
ferences among the wells depending on the progress of the 
phase transition (FIG. 1A). At the beginning (time zero) all 
wells have a uniformly whitish, milky appearance, as the MS 
are in suspension. The well with no RVV-X added (open 
circles) remains the same during the entire course of the 
experiment. After 12 minutes, corresponding to t112  for 100 
attomoles of RV V-X (solid diamonds), less opaque material is 
seen in the corresponding well. No changes are observed in 
the other wells at this time. At 26 minutes, corresponding to 
t112 for 10 attomoles of RVV-X (open squares), less opaque 
8 
material is seen in the well, as was at 12 minutes for the well 
with 100 attomoles of RVV-X. The MS in the well with the 
100 attomoles of RV V-X are coagulated by this time, and the 
well has a clear black background. This coagulation pattern is 
5 repeated in subsequent wells. Thus, the homogeneous BCC-
MS amplification cascade is adequate for the detection of 
small quantities of RVV-X by the naked eye. 
Selection of an Aptamer to RVV-X. An RNA aptamer 
binding to RVV-X was obtained via standard SELEX proto- 
10 col (17-19). The progress of the selection was monitored by 
determining the dissociation constant of the RNA-protein 
complex (Kd) and by determining the fraction of RNA that 
binds to the target protein at a the same "high" concentration 
(50 nM) of both the aptamer and the target protein in a single 
15 point binding assay. The latter assay was performed using 
both the binding buffer and the high salt buffer (binding 
buffer+300 nM NaCI) to decrease the input of nonspecifically 
bound complexes (20). The initial pool of unselected RNA 
(RNAO) had a Kd value of 550±23 nM. In a single point 
20 binding assay, 6.3% of RNAO preincubated with RV V-X was 
bound to the filter when the binding buffer was used for 
washing, and 2.2% of the RNAO stayed bound to the filter 
when the high salt buffer was used for washing, with 1.2% of 
background noise. After the ninth round of selection, K d for 
25 RNA9 decreased to 2.2±1.9 nM, and the results for the single 
point binding assay were 55% and 43% respectively, with 2% 
background noise. A consensus sequence (RNA9c) was 
derived from the analysis of 45 clones of RT-PCRed RNA9. 
The full length RNA9c (87 bases) containing the consensus 
3o 40-mer sequence flanked by the primers showed a 43% 
inhibitory effect on the RVV-X enzymatic activity in the 
RVV-X-SPZXa assay. A systematic deletion mutagenesis 
applied to RNA9c enabled the isolation of a minimal 43-mer 
RNA37s (FIG. 2A) with 84% inhibitory effect on RVV-X in 
35 the RVV-X-SPZXa assay. RNA37s also showed a concentra-
tion-dependent inhibitory effect on the RVV-X-induced clot 
formation in the BCC-MS detection system (FIG. 3A). Bind-
ing of RNA37s to RV V-X was confirmed in a gel-shift experi-
ment (FIG. 4). 
40 Allosterizing of the Aptamer to RVV-X Human VEGF165 
was chosen as an effector molecule for the construction of an 
allosteric aptamer. The choice of VEGF 165 was based on 
several criteria, including the availability of high affinity 
aptamers to VEGF 165 (21, 22), one of which was shown to be 
45 an efficient anti-VEGF 165 agent in vivo (29). Also there are 
several natural analogs of the human VEGF 165 that can be 
adequate controls for the specificity of the detection system; 
and there are commercially available highly sensitive ELISA 
assays for this protein that can serve as reference standards. 
50 An aptamer binding to VEGF165, RNA ligand VTt44 (22), 
with one base omitted from both 5'- and 3'-ends, VTt44(-2), 
(FIG. 213), was inserted into RNA37s five bases downstream 
from its 5'-end to create the allosteric aptamer RNA132 (FIG. 
2C). This structure appeared to be more stable when com- 
55 pared with the "head to tail" version, where the 5'-end of 
RNA37s was directly fused with the 3'-end of VTt44(-2) 
(AG-24.0 kcal/mol versus AG-18.0 kcal/mol) (23, 24). 
Presumably, putative RNA binding domains stayed acces-
sible for both proteins in the chimeric RNA132. A possible 
60 conformation including pseudoknots was also predicted for 
RNA132 with AG-27.0 kcal/mol (FIG. 2D) (23). 
In a gel-shift assay, RVV-X and VEGF 165 were shown to 
bind to RNA132 at about equal concentrations (FIG. 4). The 
dissociation constants for both proteins, 5.7±2.9 nM, 
65 appeared to be identical within experimental error. RNA132 
was also tested in the RVV-X-SPZXa assay and showed 86% 
inhibitory effect similar to the effect of RNA37s within 
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experimental error. As tested in the BCC-MS detection sys-
tem, concentration-dependent inhibitory effect of RNA132 
on the phase transition was also similar to RNA37s within 
experimental error. 
The Effector Molecule, VEGF165,  Reverses Inhibition of 
the Phase Transition Caused by RNA132. As was shown in 
the RNA132-controled BCC-MS detection system, VEGF165 
reversed the inhibitory effect of RNA132 on the RVV-X-
triggered phase transition in a concentration-dependent mode 
(FIG. 313). This effect suggests a competition between 
VEGF165 and RVV-X for binding to RNA132. Dynamic 
range for the effect of VEGF165 on the reversal of the phase 
transition in the RNA132-controled BCC-MS detection sys-
tem appeared to be narrow, i.e. about 10-fold range of 
VEGF165 concentrations (3-30 fmol). This was shown to be 
typical for the BCC-based detection systems (28). The sen-
sitivity ofthe detection of VEGF165 in the RNA132-controled 
BCC-MS detection system is within the lower half of the 
linear range for the VEGF 165  concentrations detected by com-
mercial ELISA assays. 
Another allosteric aptamer (RNA37sN71) modulated by a 
different effector molecule was created by fusing RNA37s 
with an aptamer to a protein tyrosine phosphatase (PTPase) 
from Yersinia enterocolitica, N71 (30). In the RNA37sN71-
controled BCC-MS detection system, the PTPase also 
reversed the inhibitory effect of RNA37sN71 on the RVV-X-
triggered phase transition in a concentration-dependent mode 
(FIG. 313), though the curve describing the relative effect of 
the PTPase was shifted to higher concentrations of PTPase as 
compared with VEGF 165 
Specificity of the BCC-MS Detection System. FIG. 5 pre-
sents the data on the specificity of the RNA132-controled 
BCC-MS detection system for human VEGF165'  Human 
VEGF1651 murineVEGF 165  and zebrafishVEGF 165  have both 
the same biological function and contain 165 of amino acids. 
Murine VEGF165 has an 89% identity with human VEGF165, 
where 147 of 165 amino acids are identical. Zebrafish 
VEGF165 has about a 62% amino acid sequence identity with 
human VEGF165.  Human VEGF121 is a truncated version of 
human VEGF165,  with 44 amino acids truncated downstream 
from position 110 of the polypeptide chain.Thus cysteine 137 
of VEGF165 that forms a photo-inducible cross-link to a uri-
dine at position 14 of RNA VTt44 (22) (which corresponds to 
position 13 of RNA VTt44(-2) and position 18 of RNA132) 
is missing in VEGF121.  Human VEGF/P1GF heterodimer is a 
protein artificially dimerized in vitro. It consists of human 
VEGF165 and Placental growth factor. The amino acid 
sequence of endocrine gland VEGF is unrelated to that of 
human VEGF. The kinetics of the clot formation were similar 
in the wells containing human VEGF165 and murine 
VEGF165' In both cases, the coagulation process was com-
plete within 40 minutes. This was not surprising, since human 
and murine VEGF165 are highly homologous. At the same 
time point (40 minutes) when the wells containing human 
VEGF165 demonstrated completed coagulation, the wells 
containing zebrafish VEGF165,  demonstrated the onset of 
coagulation. It can be explained by less homology (62%) 
between human VEGF165 and zebrafish VEGF165'  Mean-
while in the wells containing human VEGF1211  endocrine 
gland VEGF, human VEGF/P1GF, and BSA, phase transition 
has not been observed by that time. The results in FIG. 5 
clearly demonstrate the high specificity of the detection sys-
tem. 
Exploration of the Possible Mechanism of the Allosteric 
Effect. An attempt was made to find a mechanism underlying 
the competition between VEGF165 and RVV-X for the inter-
action with RNA132. DNA molecules complementary to dif- 
10 
ferent segments of RNA132 were used in the competition 
binding experiments of RVV-X and VEGF 165 to RNA132 
(see Table 1). When a full-length DNA complement to 
RNA132 (DNAI) was used, no binding was observed for 
5 either of the proteins. When DNAII and DNA III compete for 
the RVV-X binding to the 37s domain of RNA132, predict-
able low levels of RVV-X binding were detected. Annealing 
of DNAIV to the VTt44 domain of RNA132 significantly 
decreases VEGF165 binding to RNA132. When shorter DNA 
10 fragments corresponding to the VTt44 domain of RNA132 
(DNAV and DNAVI) were used for the competition, the 
impact of competing DNA on VEGF165 affinity for RNA132 
is decreased. An unexpected inhibitory effect of DNAIV and 
15 DNAV on RVV-X binding to RNA132 was also observed. A 
possible explanation is that the putative stem located between 
positions 2-8 and 28-34 in RNA132 (FIG. 2C) is involved in 
the binding of both proteins. This can result in direct steric 
competition between the proteins. One can also speculate that 
20 the decrease of RVV-X binding in the presence of DNAIV and 
DNAV can be explained by assuming an alternative folding of 
RNA132 into a structure containing pseudoknots (FIG. 2D). 
Further theoretical and experimental analysis is required to 
more clearly describe the molecular interactions resulting in 
25 allosteric properties of RNA132. 
Discussion 
In this study, an allosteric RNA aptamer-based competitive 
homogeneous detection system with readout by the naked eye 
was achieved. This became possible by coupling an allosteric 
30 RNA aptamer with the biochemical signal amplification cas-
cade, BCC-MS. The signal amplification cascade results in an 
eye-visible phase transition, i.e. formation of the precipitate 
of polystyrene microspheres bound to clotted fibrin. The 
allosteric aptamer contains a domain that binds to RVV-X 
35 thus inhibiting BCC. There is another domain on the allos-
teric aptamer, which binds to an effector molecule reversing 
the effect of the first domain. The latter domain of the aptamer 
is the only variable part of the detection system. Therefore, 
adjusting the detection system to a new effector molecule will 
40 involve only one molecular component an aptamer to the 
effector molecule. Further, the detection system requires only 
2 pipetting cycles compared with 10 in the case of ELISA, and 
it requires less than an hour for its completion, compared with 
4.5 hours for ELISA. Most importantly, the naked eye is used 
45 as a readout instrument instead of expensive and rarely avail-
able equipment. These features make the detection system a 
good candidate as a platform for fieldable detection systems 
and make it competitive with ELISA. 
While the present invention has been described herein with 
50 specific details by way of illustrations and examples, those of 
ordinary skill in the art will readily recognize that numerous 
modifications, substitutions, and alterations are possible 
without departing from the spirit and scope of the invention. 
It is intended that all of these modifications and variations be 
55 within the scope of the present invention as described and 
claimed herein, and that the invention be limited only by the 
scope of the claims which follow, and that such claims be 
interpreted as broadly as reasonable. 
60 	 REFERENCES 
The following references are cited herein. The entire dis-
closure of each reference is relied upon and incorporated by 
reference herein. 
65 1. Osborne, S. E., Matsumura, I., and Ellington, A. D. (1997) 
Aptamers as therapeutic and diagnostic reagents: problems 
and prospects, Curr. Opin. Chem. Biol. 1, 5-9. 
US 8,324,357 B2 
11 
2. Jayasena, S. D. (1999) Aptamers: an emerging class of 
molecules that rival antibodies in diagnostics, Clinical 
Chem. 45, 1628-1650. 
3. Brody, E. N., and Gold, L. (2000) Aptamers as therapeutic 
and diagnostic agents, Molec. Biotechnol. 74, 5-13. 
4. Jhaveri, S. D., Kirby, R., Conrad, R., Maglott, E. J., Bowser, 
M., Kennedy, R. T., Glick, G., and Ellington, A. D. (2000) 
Designed signaling aptamers that transduce molecular rec-
ognition to changes in fluorescent intensity, J. Am. Chem. 
Soc, 122, 2469-2473. 
5. Jhaveri, S., Rajendran, M., and Ellington, A. D. (2000) In 
vitro selection of signaling aptamers, Nature Biotechnol. 
18,1293-1297. 
6. Hamaguchi, N., Ellington, A., and Stanton, M. (2001) 
Aptamer beacons for direct detection of proteins, Anal. 
Biochem. 294, 126-131. 
7. Silverman, S. K. (2003) Rube Goldberg goes (ribo) 
nuclear? Molecular switches and sensors made of RNA, 
RNA, 9, 377-383. 
8. Stojanovic, M. N., and Kolpashchikov, D. M. (2004) 
Modular aptameric sensors, J. Am. Chem. Soc. 126, 9266-
9270. 
9. Wang, X-L., Li, F., Su, Y-H., Sun, X, Li, X-B., Schluesener, 
H. J., Tang, F. and Xu, S-Q. (2004) Ultrasensitive detection 
of protein using an aptamer-based exonuclease protection 
assay, Analytical Chem. 76, 5605-5610. 
10. Tombelli, S.; Minunni, M.; Mascini, M. (2005) Analytical 
applications of aptamers, Biosensors and Bioelectronics 
20,2424-2434. 
11. Soukup, G. A. (2004) Aptamers meet allostery, Chem. 
Biol. 11, 1031-1032. 
12. Wu, L., and Curran, J. F. (1999) An allosteric synthetic 
DNA, Nucleic Acid Res. 27, 1512-1516. 
13. Vuyisich, M., and Beal, P. A. (2002) Controlling protein 
activity with ligand-regulated RNA aptamers, Chem. Biol. 
9,907-913. 
14. Buskirk, A. R., Landrigan, A. and Liu D. R. (2004) Engi-
neering a ligand-dependent RNA transcriptional activator, 
Chem. Biol. 11, 1157-1163. 
15. Nutiu, R., and Li, Y. (2004) Structure-switching signaling 
aptamers: transducing molecular recognition into fluores-
cence signaling, Chem. Eur. J. 10, 1868-1876. 
16. Cong, X., and Nielsen-Hamilton, M. (2005) Allosteric 
aptamers: Targeted reversibly attenuated probes, Biochem-
istry 44, 7945-7954. 
17. Fitzwater, T. and Polisky, B. (1996) A SELEX primer, 
Methods in Enzymology 267, 275-301. 
18. Pollard, J., Bell, S. D., and Ellington, A. D. (2000) Design, 
synthesis, and amplification of DNA pools for in vitro 
selection, Current Protocols in Nucleic Acid Chemistry 
9.2.1-9.2.23. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 5 
<210> SEQ ID NO 1 
<211> LENGTH: 43 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic oligonucleotide 
12 
19. Jhaveri, S. D, and Ellington, A. D. (2000) In vitro selec-
tion of RNA aptamers to a protein target by filter immobi-
lization, Current Protocols in Nucleic Acid Chemistry 
9.3.1-9.3.25. 
5 20. Cox, J. C., Hayhurst, A., Hesselberth, J., Bayer, T. S., 
Georgiou, G., and Ellington, A. D. (2002) Automated 
selection of aptamers against protein targets translated in 
vitro: from gene to aptamer, Nucleic Acid Res. 30, e108, 
1-14. 
10 
21. Jelinek, D., Green, L. S., Bell, C., and Janjic, N. (1994) 
Inhibition of receptor binding by high-affinity RNA 
ligands to vascular endothelial growth factor, Biochemistry 
33, 10450-10456. 
22. Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gilette, 
W. L., Henninger, D. D., Claesson-Welsh, L., and Janjic, N. 
15 (1998) 2'-Fluoropyrimidine RNA-based aptamers to the 
165-amino acid form of vascular endothelial growth factor 
(VEGF 165), J. Biol. Chem. 273, 20556-20567. 
23. Dirks, R. M., and Pierce, N. A. (2003) A partition function 
algorithm for nucleic acid secondary structure including 
20 	 pseudoknots, J. Comput. Chem. 24, 1664-1677. 
24. Dirks, R. M., and Pierce, N. A (2004) An algorithm for 
computing nucleic acid base pairing probabilities includ-
ing pseudoknots, J. Comput. Chem. 25, 1295-1304. 
25. Han, K., and Byun, Y. (2003) PseudoViewer2: visualiza-
25 tion of RNA pseudoknots of any type, Nucleic Acid Res. 
31, 3432-3440. 
26. Strachan, N. J. C., and Ogden, I. D. (2000) A sensitive 
microsphere coagulation ELISA for Escherichia coli 
0157:H7 using Russell's viper venom, FEMS Microbiol. 
30 	 Lett. 186, 79-84. 
27. Gowda, D. C., Jackson, C. M., Hensley, P., and Davidson, 
E. A. (1994) Factor X activating glycoprotein of Russell's 
viper venom. Polypeptide composition and characteriza-
tion of the carbohydrate moieties, J. Biological Chemistry 
35 	 269, 10644-10650. 
28. Doellgast, G. J., Triscott, M. X., Beard, G.A., Bottoms, J. 
D., Cheng, T., Roh, B. H., Roman, M. G., Hall, P. A., and 
Brown, J. E. (1993) Sensitive enzyme-linked Immunosor-
bent assay for detection of Clostridium botulinum neuro- 
40 toxins A, B, and E using signal amplification via enzyme-
linked coagulation assay, J. Clin. Microbiol. 31, 2402-
2409. 
29. Fish, G., Haller, J. A., Ho, A. C., Klein, M., Loewenstein, 
J., Martin, D., Orth, D., Rosen, R. B., Sanislo, S., Schwartz, 
45 S. D. et al. (2003) Anti-vascular endothelial growth factor 
therapy for subfoveal choroidal neovascularization sec-
ondary to age related macular degeneration. Phase II study 
results, Ophthalmology, 110, 979-986. 
30. Dell, S. D., Denu, J. M., Dixon, J. E., and Ellington, A. D. 
50 (1998) RNA molecules that bind to and inhibit the active 
site of tyrosine phosphatase, J. Biol. Chem. 273, 14309-
14314. 
<400> SEQUENCE: 1 
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-continued 
gggagcuccu ugagcagucg auuaguuucg acaggaggcu cac 	 43 
<210> SEQ ID NO 2 
<211> LENGTH: 25 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic oligonucleotde 
<400> SEQUENCE: 2 
ggaaucagug aaugcuuaua caucc 	 25 
<210> SEQ ID NO 3 
<211> LENGTH: 68 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic oligonucleotide 
<400> SEQUENCE: 3 
gggagggaau cagugaaugc uuauacaucc cuccuugagc agucgauuag uuucgacagg 	 60 
aggcucac 	 68 
<210> SEQ ID NO 4 
<211> LENGTH: 68 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic oligonucleotde 
<400> SEQUENCE: 4 
gggagggaau cagugaaugc uuauacaucc cuccuugagc agucgauuag uuucgacagg 	 60 
aggcucac 	 68 
<210> SEQ ID NO 5 
<211> LENGTH: 80 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic oligonucleotide 
<400> SEQUENCE: 5 
gggagucagg gagcgaggac cagacgacgu accuaacccu aacuccuuga gcagucgauu 	 60 
aguuucgaca ggaggcucac 	 80 
What is claimed is: 4. The detection system according to claim 1, wherein the 
1. A detection system comprising: 50 second aptamer is one specific forhuman vascular endothelial 
a) a fusion aptamer formed by fusing a first aptamer to a growth factor (VEGF 165) or a protein tyrosine phosphatase 
second aptamer; from Yersinia enterocolitica. 
b) Russell's viper venom factor X activator (RVV-X); and 5. The detection system according to claim 1, wherein said 
c) a biochemical signal amplification subsystem compris- fusion aptamer is one having a sequence according to SEQ ID ing blood coagulation components and a signaling 55 	 No: 5. 
agent, 
wherein said first aptamer is one specific for RVV-X, said 6. A fusion aptamer formed by fusing a first aptamer spe- 
second aptamer is one specific for a target molecule to be cific for RW-X and a second aptamer specific for a target 
detected, and said signaling agent is one capable of molecule. 
interacting with the product of blood coagulation cas- 60 	 7 . The fusion aptamer of claim 6, wherein said first aptamer 
cade reaction to give a visual signal readable by the is one having a sequence according to SEQ ID No: 1. 
naked eye. 8. The fusion aptamer of claim 6, wherein said fusion 
2. The detection system according to claim 1, wherein the aptamer having a sequence according to SEQ ID No: 3. 
first aptamer is one having a sequence according to SEQ ID 9. The fusion aptamer of claim 6, wherein said fusion 
No: 1. 65 aptamer having a sequence according to SEQ ID No: 5. 
3. The detection system according to claim 1, wherein said 10. A method for detecting a target molecule in a sample, 
signaling agent is a polystyrene microsphere. comprising: 
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contacting the sample with RVV-X, a fusion aptamer, 
blood coagulation components and a signaling agent, 
wherein said fusion aptamer is formed by fusing a first 
aptamer specific for RVV-X and a second aptamer spe-
cific for said target molecule, said signaling agent is one 
capable of interacting with the product of blood coagu-
lation cascade reaction to give a visual signal readable 
by the naked eye, and 
whereby presence of the target molecule in the sample 
initiates a blood coagulation cascade reaction to give a 
visual signal. 
11. The method of claim 10, wherein said RVV-X, fusion 
aptamer, blood coagulation components, and signaling agent 
are pre-mixed together prior to contacting the sample. 
12. The method of claim 10, wherein said sample, blood 
coagulation components and signaling agent are brought in 
16 
contact first before a mixture of RVV-X and the fusion 
aptamer are added. 
13. The method of claim 10, wherein said first aptamer 
specific for RVV-X is one having a sequence according to 
5 SEQ ID No: 1. 
14. The method of claim 10, wherein said fusion aptamer is 
one having a sequence according to SEQ ID No: 3 or SEQ ID 
No: 5. 
15. The method of claim 10, wherein said target molecule 
10 is one selected from VEGF 165 or a protein tyrosin phos-
phatase. 
16. The method of claim 10, wherein said signaling agent 
is a polystyrene microsphere. 
15 
